Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L, Pasco S, Hornebeck W, Maquart FX, Monboisse JC. Ramont L, et al. Among authors: pasco s. Exp Cell Res. 2003 Nov 15;291(1):1-10. doi: 10.1016/s0014-4827(03)00336-7. Exp Cell Res. 2003. PMID: 14597403
Elastin-derived peptides enhance melanoma growth in vivo by upregulating the activation of Mcol-A (MMP-1) collagenase.
Devy J, Duca L, Cantarelli B, Joseph-Pietras D, Scandolera A, Rusciani A, Parent L, Thevenard J, Pasco SB, Tarpin M, Martiny L, Debelle L. Devy J, et al. Among authors: pasco sb. Br J Cancer. 2010 Nov 9;103(10):1562-70. doi: 10.1038/sj.bjc.6605926. Epub 2010 Oct 19. Br J Cancer. 2010. PMID: 20959825 Free PMC article.
Control of melanoma cell invasion by type IV collagen.
Pasco S, Brassart B, Ramont L, Maquart FX, Monboisse JC. Pasco S, et al. Cancer Detect Prev. 2005;29(3):260-6. doi: 10.1016/j.cdp.2004.09.003. Epub 2004 Nov 23. Cancer Detect Prev. 2005. PMID: 15936594 Review.
An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion.
Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. Maquart FX, et al. Among authors: pasco s. Crit Rev Oncol Hematol. 2004 Mar;49(3):199-202. doi: 10.1016/j.critrevonc.2003.06.007. Crit Rev Oncol Hematol. 2004. PMID: 15036260 Review.
Control of melanoma progression by various matrikines from basement membrane macromolecules.
Pasco S, Ramont L, Maquart FX, Monboisse JC. Pasco S, et al. Crit Rev Oncol Hematol. 2004 Mar;49(3):221-33. doi: 10.1016/j.critrevonc.2003.09.006. Crit Rev Oncol Hematol. 2004. PMID: 15036262 Review.
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX, Monboisse JC. Pasco S, et al. Exp Cell Res. 2004 Dec 10;301(2):251-65. doi: 10.1016/j.yexcr.2004.07.036. Exp Cell Res. 2004. PMID: 15530861
[Biological effects of collagen I and IV peptides].
Pasco S, Ramont L, Maquart FX, Monboisse JC. Pasco S, et al. J Soc Biol. 2003;197(1):31-9. J Soc Biol. 2003. PMID: 12868264 Review. French.
The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
Floquet N, Pasco S, Ramont L, Derreumaux P, Laronze JY, Nuzillard JM, Maquart FX, Alix AJ, Monboisse JC. Floquet N, et al. Among authors: pasco s. J Biol Chem. 2004 Jan 16;279(3):2091-100. doi: 10.1074/jbc.M307736200. Epub 2003 Oct 28. J Biol Chem. 2004. PMID: 14583633
Matrikines in the regulation of extracellular matrix degradation.
Maquart FX, Bellon G, Pasco S, Monboisse JC. Maquart FX, et al. Among authors: pasco s. Biochimie. 2005 Mar-Apr;87(3-4):353-60. doi: 10.1016/j.biochi.2004.10.006. Biochimie. 2005. PMID: 15781322 Review.
A specific sequence of the noncollagenous domain of the alpha3(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells.
Pasco S, Han J, Gillery P, Bellon G, Maquart FX, Borel JP, Kefalides NA, Monboisse JC. Pasco S, et al. Cancer Res. 2000 Jan 15;60(2):467-73. Cancer Res. 2000. PMID: 10667602
23 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback